Metabolic Management
|
July 12, 2024

Insulin Resistance & Type 1 Diabetes - What You Need to Know

Medically Reviewed by
Updated On
December 13, 2024

Insulin resistance is a common metabolic dysfunction that can lead to various chronic illnesses, including type 2 diabetes, cardiovascular disease, and obesity. Evidence suggests that at least 25% of adults in the United States who don't have diabetes are insulin-resistant.Β 

Insulin resistance occurs when the body's cells fail to respond to insulin. This causes more insulin to be produced, leading to chronically high insulin levels.Β 

While insulin resistance is classically associated with type 2 diabetes mellitus, this article will detail how it can occur in type 1 diabetes mellitus, what causes it, its effects, and how to manage it.

[signup]

What Is Insulin Resistance?

Insulin has two main functions within the body:

  • Acting as a hormone to reduce blood glucose levels.
  • Acting as a signaling molecule for cells in virtually all body organs.Β 

Insulin resistance is a disruption of metabolism that occurs when cells of the body do not respond to insulin stimulation.Β 

To understand insulin resistance, it is necessary to understand the physiology of insulin:Β 

In a healthy patient, insulin is released by the beta cells of the pancreas in response to a rise in blood glucose, which occurs after the ingestion of carbohydrates. When a patient eats carbohydrates, and the body metabolizes them, blood glucose rises. This signals the pancreas to release insulin. Insulin then helps return blood glucose levels to the normal range by telling cells how to use the glucoseβ€”either to send it to various organs for energy or to store it as fat (adipose tissue).

However, when this process is dysfunctional, insulin resistance occurs, continually stimulating the pancreas to produce more insulin and causing blood glucose levels to remain consistently elevated.Β 

The Prevalence of Insulin Resistance in Type 1 Diabetes

In past decades, type 1 diabetes mellitus most often began in childhood. Its pathophysiology solely reflected the lack of insulin release from the pancreas, and patients responded completely to treatment with exogenous insulin. Type 2 diabetes mellitus was traditionally seen only in adult patients, and its pathophysiology depended upon the effects of insulin resistance. While the pancreas still produced insulin, the body was resistant to the effects of the insulin it made.Β 

It highlights factors such as genetic susceptibility, an obesogenic environment, increased food intake, and obesity.

However, the landscape of diabetes pathology has changed. The incidences of overweight and obesity in the cases of type 1 diabetes mellitus continue to increase, which is one factor that has led to a different phenotype that once dominated the disease of type 1 diabetes mellitus.Β 

Despite the common misconception that insulin resistance only affects patients with type 2 diabetes, increasing numbers of patients with type 1 diabetes mellitus develop secondary insulin resistance for many reasons.

In addition, type 1.5 diabetes mellitus has emerged as a pathophysiologic blend of type 1 and type 2 diabetes mellitus. It typically presents in adults with a more gradual onset of illness. Type 1.5 diabetes mellitus includes a degree of autoimmune pancreatic beta cell destruction, causing insulin deficiency and insulin resistance. This requires special considerations in terms of treatment.

Causes of Insulin Resistance in Type 1 Diabetes

Role of Exogenous Insulin

Taking exogenous insulin can result in over-insulinization, as insulin needs fluctuate based on many factors. Endogenous insulin release is designed to physiological needs, supplying the right amount of insulin to meet the body’s demands. However, taking exogenous insulin requires estimated dosing, and over time, exposing the body to excess insulin can lead to decreased cellular response to insulin stimulation.Β 

Diabetes Mellitus Risk Factors

Duration

The duration of type 1 diabetes mellitus significantly influences whether or not insulin resistance is present. A longer duration of type 1 diabetes leads to more exposure to exogenous insulin and a higher likelihood of other metabolic side effects, like obesity, hypertension, and dyslipidemia. These factors increase the risk of developing insulin resistance over time.

Poor Glycemic Control

Poor glycemic control in type 1 diabetes (due to poor diet, limited physical activity, medication side effects, or the presence of autoantibodies) leads to the use of higher doses of insulin. The use of higher doses of exogenous insulin causes weight gain, which can lead to insulin resistance.

Impacts of Other Medical Conditions

Hormonal Changes

Abnormal levels of not only insulin but also other neuroendocrine hormones, including glucagon-like peptide-1 (GLP-1), cortisol, somatostatin, and more, reduce the ability of endogenous insulin to promote optimal glycemic control.

Chronic Inflammation

Chronic inflammation increases the risk of developing insulin resistance. Oxidative stress is an underlying factor in many of these cases because it interferes with insulin signaling and predisposes to hyperglycemia, poor lipid metabolism, and dysregulations in insulin-like growth factor-1. Chronic inflammation also leads to neuroendocrine hormone imbalances, reducing the effect of endogenous insulin on glycemic control.

Overweight and Obesity

Increased consumption of refined carbohydrates and added sugars, a diet overall high in processed foods, and a sedentary lifestyle have led to an increase in overweight and obesity in patients with type 1 diabetes mellitus. While type 1 diabetes was previously characterized by an absolute insulin deficiency, the increased prevalence of overweight and obesity and the adverse metabolic consequences have shifted its pathophysiology also to include insulin resistance.

Metabolic Disease

Metabolic syndrome or its components, including impaired fasting glucose, dyslipidemia, overweight or obesity, and hypertension, increases the risk of developing insulin resistance.

Genetic and Lifestyle Factors

Lifestyle Factors

A diet high in processed foods and refined carbohydrates and a sedentary lifestyle is strongly associated with developing insulin resistance.

Genetic Predisposition

The presence of specific genes has been shown to predispose to insulin resistance. Variations in genes coding for insulin signaling or other genetic factors affecting mitochondrial activity, inflammatory mediators, and lipid metabolism are linked to a greater risk of insulin resistance.

The following are examples of genetic markers that increase the risk for insulin resistance:

  • PTB1
  • LEPR
  • RETN
  • SLC2A4

Other Medications

Aside from too much exogenous insulin, other medications can promote insulin resistance.Β  These include:

Addressing Insulin Resistance in Type 1 Diabetes

Lifestyle Modifications

Lifestyle interventions are an important part of managing insulin resistance.Β 

Diet plays a significant role in insulin sensitivity. A healthful diet can help preserve or restore insulin sensitivity, while a poor diet high in refined carbohydrates and proinflammatory foods promotes insulin resistance.Β 

  • Prioritizing a diet of whole, nutrient-dense foods while also minimizing refined sugars and processed foods helps regulate blood glucose and improves insulin sensitivity.
  • Emphasizing healthy fats, such as omega-3 fatty acids, helps reduce inflammation and improves insulin sensitivity.
  • Focusing on high-fiber foods like vegetables, fruits, whole grains, and legumes helps control insulin release and promotes insulin sensitivity.

Regular physical activity is important in promoting insulin sensitivity.Β 

  • Cardiovascular exercise improves insulin sensitivity by increasing glucose uptake and utilization in muscles. It also helps with healthy weight maintenance by increasing energy expenditure and promoting fat oxidation.Β 
  • Strength training, which includes weight lifting and bodyweight exercises, enhances insulin sensitivity by increasing muscle mass and muscle glucose uptake. Strength training also helps increase and preserve lean body mass, which helps maintain a healthy weight long-term by increasing resting energy expenditure.Β 

Medications and Advanced Therapies

Traditionally, insulin-sensitizing medications, such as metformin and also the newer glucagon-like peptide-1 (GLP-1) receptor agonists, have been used for type 2 diabetes mellitus. While non-insulin therapies are not FDA-approved for use in type 1 diabetes mellitus, evidence suggests insulin-sensitizing medications may be effective in treating insulin resistance in cases of type 1 diabetes mellitus. In addition, GLP-1 receptor agonists may also help regulate glucagon secretion from pancreatic alpha cells.Β 

Health Consequences of Insulin Resistance in Type 1 Diabetes

When insulin resistance occurs in type 1 diabetes mellitus, it increases the risk of other complications:

[signup]

Key Takeaways

  • Insulin resistance was previously associated with only type 2 diabetes mellitus, but it increasingly affects patients with type 1 diabetes as well.
  • Type 1.5 diabetes mellitus has emerged as a blend of the underlying pathophysiologies of type 1 and type 2 diabetes.
  • Several risk factors predispose to insulin resistance within type 1 diabetes.
  • Many lifestyle changes can help control underlying insulin resistance in any diabetes form.
  • Insulin-sensitizing medications may benefit some type 1 diabetes cases where insulin resistance is present.
  • Understanding the underlying risk factors and strategies to manage insulin resistance will help prevent potential long-term health consequences associated with insulin resistance in type 1 diabetes.Β 

Insulin resistance is a common metabolic dysfunction that may contribute to various chronic conditions, including type 2 diabetes, cardiovascular disease, and obesity. Evidence suggests that at least 25% of adults in the United States who don't have diabetes may be insulin-resistant.Β 

Insulin resistance occurs when the body's cells do not respond effectively to insulin. This can lead to the body producing more insulin, resulting in higher insulin levels.Β 

While insulin resistance is often associated with type 2 diabetes mellitus, this article will explore how it can occur in type 1 diabetes mellitus, what may cause it, its potential effects, and ways to manage it.

[signup]

What Is Insulin Resistance?

Insulin has two main functions within the body:

  • Acting as a hormone to help manage blood glucose levels.
  • Acting as a signaling molecule for cells in virtually all body organs.Β 

Insulin resistance is a disruption of metabolism that occurs when cells of the body do not respond to insulin stimulation.Β 

To understand insulin resistance, it is necessary to understand the physiology of insulin:Β 

In a healthy individual, insulin is released by the beta cells of the pancreas in response to a rise in blood glucose, which occurs after the ingestion of carbohydrates. When carbohydrates are consumed and metabolized, blood glucose rises. This signals the pancreas to release insulin. Insulin then helps return blood glucose levels to the normal range by guiding cells on how to use the glucoseβ€”either to send it to various organs for energy or to store it as fat (adipose tissue).

However, when this process does not function properly, insulin resistance may occur, continually stimulating the pancreas to produce more insulin and causing blood glucose levels to remain consistently elevated.Β 

The Prevalence of Insulin Resistance in Type 1 Diabetes

In past decades, type 1 diabetes mellitus most often began in childhood. Its pathophysiology solely reflected the lack of insulin release from the pancreas, and patients responded completely to treatment with exogenous insulin. Type 2 diabetes mellitus was traditionally seen only in adult patients, and its pathophysiology depended upon the effects of insulin resistance. While the pancreas still produced insulin, the body was resistant to the effects of the insulin it made.Β 

It highlights factors such as genetic susceptibility, an obesogenic environment, increased food intake, and obesity.

However, the landscape of diabetes pathology has changed. The incidences of overweight and obesity in the cases of type 1 diabetes mellitus continue to increase, which is one factor that has led to a different phenotype that once dominated the disease of type 1 diabetes mellitus.Β 

Despite the common misconception that insulin resistance only affects patients with type 2 diabetes, increasing numbers of patients with type 1 diabetes mellitus develop secondary insulin resistance for many reasons.

In addition, type 1.5 diabetes mellitus has emerged as a pathophysiologic blend of type 1 and type 2 diabetes mellitus. It typically presents in adults with a more gradual onset of illness. Type 1.5 diabetes mellitus includes a degree of autoimmune pancreatic beta cell destruction, causing insulin deficiency and insulin resistance. This requires special considerations in terms of management.

Causes of Insulin Resistance in Type 1 Diabetes

Role of Exogenous Insulin

Taking exogenous insulin can result in over-insulinization, as insulin needs fluctuate based on many factors. Endogenous insulin release is designed to meet physiological needs, supplying the right amount of insulin to meet the body’s demands. However, taking exogenous insulin requires estimated dosing, and over time, exposing the body to excess insulin can lead to decreased cellular response to insulin stimulation.Β 

Diabetes Mellitus Risk Factors

Duration

The duration of type 1 diabetes mellitus significantly influences whether or not insulin resistance is present. A longer duration of type 1 diabetes leads to more exposure to exogenous insulin and a higher likelihood of other metabolic side effects, like obesity, hypertension, and dyslipidemia. These factors may increase the risk of developing insulin resistance over time.

Poor Glycemic Control

Poor glycemic control in type 1 diabetes (due to poor diet, limited physical activity, medication side effects, or the presence of autoantibodies) may lead to the use of higher doses of insulin. The use of higher doses of exogenous insulin can contribute to weight gain, which may lead to insulin resistance.

Impacts of Other Medical Conditions

Hormonal Changes

Abnormal levels of not only insulin but also other neuroendocrine hormones, including glucagon-like peptide-1 (GLP-1), cortisol, somatostatin, and more, may reduce the ability of endogenous insulin to support optimal glycemic control.

Chronic Inflammation

Chronic inflammation may increase the risk of developing insulin resistance. Oxidative stress is an underlying factor in many of these cases because it can interfere with insulin signaling and predispose individuals to hyperglycemia, poor lipid metabolism, and dysregulations in insulin-like growth factor-1. Chronic inflammation may also lead to neuroendocrine hormone imbalances, reducing the effect of endogenous insulin on glycemic control.

Overweight and Obesity

Increased consumption of refined carbohydrates and added sugars, a diet overall high in processed foods, and a sedentary lifestyle have led to an increase in overweight and obesity in patients with type 1 diabetes mellitus. While type 1 diabetes was previously characterized by an absolute insulin deficiency, the increased prevalence of overweight and obesity and the adverse metabolic consequences have shifted its pathophysiology also to include insulin resistance.

Metabolic Disease

Metabolic syndrome or its components, including impaired fasting glucose, dyslipidemia, overweight or obesity, and hypertension, may increase the risk of developing insulin resistance.

Genetic and Lifestyle Factors

Lifestyle Factors

A diet high in processed foods and refined carbohydrates and a sedentary lifestyle is strongly associated with developing insulin resistance.

Genetic Predisposition

The presence of specific genes has been shown to predispose individuals to insulin resistance. Variations in genes coding for insulin signaling or other genetic factors affecting mitochondrial activity, inflammatory mediators, and lipid metabolism are linked to a greater risk of insulin resistance.

The following are examples of genetic markers that may increase the risk for insulin resistance:

  • PTB1
  • LEPR
  • RETN
  • SLC2A4

Other Medications

Aside from too much exogenous insulin, other medications may promote insulin resistance.Β  These include:

Addressing Insulin Resistance in Type 1 Diabetes

Lifestyle Modifications

Lifestyle interventions are an important part of managing insulin resistance.Β 

Diet plays a significant role in insulin sensitivity. A healthful diet may help preserve or restore insulin sensitivity, while a poor diet high in refined carbohydrates and proinflammatory foods may promote insulin resistance.Β 

  • Prioritizing a diet of whole, nutrient-dense foods while also minimizing refined sugars and processed foods may help regulate blood glucose and improve insulin sensitivity.
  • Emphasizing healthy fats, such as omega-3 fatty acids, may help reduce inflammation and improve insulin sensitivity.
  • Focusing on high-fiber foods like vegetables, fruits, whole grains, and legumes may help control insulin release and promote insulin sensitivity.

Regular physical activity is important in promoting insulin sensitivity.Β 

  • Cardiovascular exercise may improve insulin sensitivity by increasing glucose uptake and utilization in muscles. It also helps with healthy weight maintenance by increasing energy expenditure and promoting fat oxidation.Β 
  • Strength training, which includes weight lifting and bodyweight exercises, may enhance insulin sensitivity by increasing muscle mass and muscle glucose uptake. Strength training also helps increase and preserve lean body mass, which may help maintain a healthy weight long-term by increasing resting energy expenditure.Β 

Medications and Advanced Therapies

Traditionally, insulin-sensitizing medications, such as metformin and also the newer glucagon-like peptide-1 (GLP-1) receptor agonists, have been used for type 2 diabetes mellitus. While non-insulin therapies are not FDA-approved for use in type 1 diabetes mellitus, evidence suggests insulin-sensitizing medications may be effective in addressing insulin resistance in cases of type 1 diabetes mellitus. In addition, GLP-1 receptor agonists may also help regulate glucagon secretion from pancreatic alpha cells.Β 

Health Consequences of Insulin Resistance in Type 1 Diabetes

When insulin resistance occurs in type 1 diabetes mellitus, it may increase the risk of other complications:

[signup]

Key Takeaways

  • Insulin resistance was previously associated with only type 2 diabetes mellitus, but it increasingly affects patients with type 1 diabetes as well.
  • Type 1.5 diabetes mellitus has emerged as a blend of the underlying pathophysiologies of type 1 and type 2 diabetes.
  • Several risk factors may predispose individuals to insulin resistance within type 1 diabetes.
  • Many lifestyle changes may help manage underlying insulin resistance in any diabetes form.
  • Insulin-sensitizing medications may benefit some type 1 diabetes cases where insulin resistance is present.
  • Understanding the underlying risk factors and strategies to manage insulin resistance may help prevent potential long-term health consequences associated with insulin resistance in type 1 diabetes.Β 
The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Learn more

No items found.

Lab Tests in This Article

No lab tests!
  1. Abbasi F, Lamendola C, Harris CS, et al. Statins Are Associated With Increased Insulin Resistance and Secretion. Arterioscler Thromb Vasc Biol. 2021;41(11):2786-2797. https://pubmed.ncbi.nlm.nih.gov/34433298/
  2. Aedh AI, Alshahrani MS, Huneif MA, Pryme IF, Oruch R. A Glimpse into Milestones of Insulin Resistance and an Updated Review of Its Management. Nutrients. 2023;15(4):921. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960458/
  3. Bakris G, Molitch M, Zhou Q, et al. Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. J Cardiometab Syndr. 2008;3(1):18-25. https://pubmed.ncbi.nlm.nih.gov/18326972/
  4. Beaupere C, Liboz A, Fève B, Blondeau B, Guillemain G. Molecular Mechanisms of Glucocorticoid-Induced Insulin Resistance. Int J Mol Sci. 2021;22(2):623. https://pubmed.ncbi.nlm.nih.gov/33435513/
  5. Bertagna, B. (2024, January 10). The Diabetes Diet: Nutritional Guidelines to Help Manage Blood Sugar. Rupa Health. https://www.rupahealth.com/post/the-diabetes-diet-nutritional-guidelines-to-help-manage-blood-sugar
  6. Beysel S, Unsal IO, Kizilgul M, Caliskan M, Ucan B, Cakal E. The effects of metformin in type 1 diabetes mellitus. BMC Endocr Disord. 2018;18(1):1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771191/
  7. Burghardt KJ, Seyoum B, Mallisho A, Burghardt PR, Kowluru RA, Yi Z. Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies. Prog Neuropsychopharmacol Biol Psychiatry. 2018;83:55-63. https://pubmed.ncbi.nlm.nih.gov/29325867/
  8. Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petrie JR. Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?. Diabetologia. 2013;56(7):1462-1470. https://pubmed.ncbi.nlm.nih.gov/23613085/
  9. Cloyd, J. (2023, April 10). A Functional Medicine Hypertension Protocol. Rupa Health. https://www.rupahealth.com/post/functional-medicine-hypertension-protocol
  10. Cloyd, J. (2023, December 1). A Functional Medicine Protocol for Balancing Blood Sugar. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-protocol-for-balancing-blood-sugar
  11. Cloyd, J. (2023, August 25). A Root Cause Medicine Protocol for Patients with Type 1.5 Diabetes: Testing, Therapeutic Diet, and Supportive Supplements. Rupa Health. https://www.rupahealth.com/post/a-root-cause-medicine-protocol-for-patients-with-type-1-5-diabetes-testing-therapeutic-diet-and-supportive-supplements
  12. Cloyd, J. (2023, May 17). The Role of Nutrition and Dietary Supplements in Preventing and Managing Cardiovascular Disease. Rupa Health. https://www.rupahealth.com/post/the-role-of-nutrition-and-dietary-supplements-in-preventing-and-managing-cardiovascular-disease
  13. Cloyd, J. (2024, March 1). What is Hyperlipidemia? Symptoms, Testing, and Treatments. Rupa Health. https://www.rupahealth.com/post/what-is-hyperlipidemia-symptoms-testing-and-treatments
  14. Coats AJS. Beta-blockers, hypertension, and weight gain: the farmer, the chicken, and the egg. Hong Kong Med J. 2020;26(1):6-7. https://pubmed.ncbi.nlm.nih.gov/32077860/
  15. Coleman, E. (2024, May 31.) 6 Natural Ways to Enhance Insulin Sensitivity. Rupa Health. https://www.rupahealth.com/post/improve-insulin-sensitivity
  16. Cox, AD. (2022, September 8). Type 1 Diabetes: Conventional and Functional Medicine Treatments. Rupa Health. https://www.rupahealth.com/post/a-root-cause-approach-to-managing-type-1-diabetes
  17. DeCesaris, L. (2023, July 18). Mitochondria: What They Are, Why We Should Care, and How to Support Them Using Functional Medicine Strategies. Rupa Health. https://www.rupahealth.com/post/mitochondria-what-they-are-why-we-should-care-and-how-to-support-them-using-functional-medicine-strategies
  18. DeGeeter M, Williamson B. Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors. J Pharm Pract. 2016;29(2):144-159. https://pubmed.ncbi.nlm.nih.gov/25312263/
  19. DePorto, T. (2023, January 6). Omega-3s: The Superfood Nutrient You Need to Know About. Rupa Health. https://www.rupahealth.com/post/omega-3s-the-superfood-nutrient-you-need-to-know-about
  20. Diorio, B. (2023, April 17). Could Your Patients Benefit from the Phytonutrient Spectrum Food Plan? Rupa Health. https://www.rupahealth.com/post/could-your-patients-benefits-from-the-phytonutrient-spectrum-food-plan
  21. Feingold KR. Triglyceride Lowering Drugs. In: Feingold KR, Anawalt B, Blackman MR, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; January 18, 2024. https://pubmed.ncbi.nlm.nih.gov/28402615/
  22. Gerow, S. (2024, May 31). Cortisol Test: Understanding Your Stress Hormone Levels. Rupa Health. https://www.rupahealth.com/post/cortisol-test-understanding-your-stress-hormone-levels
  23. Greabu M, Badoiu SC, Stanescu-Spinu II, et al. Drugs Interfering with Insulin Resistance and Their Influence on the Associated Hypermetabolic State in Severe Burns: A Narrative Review. Int J Mol Sci. 2021;22(18):9782. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466307/
  24. Greenan, S. (2021, October 11). 7 Early Signs of Insulin Resistance. Rupa Health. https://www.rupahealth.com/post/what-is-insulin-resistance
  25. Guyton J, Jeon M, Brooks A. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. Am J Health Syst Pharm. 2019;76(21):1739-1748. https://pubmed.ncbi.nlm.nih.gov/31612934/
  26. Henry, E. (2022, January 4). How to Reverse Weight Gain and Slowed Metabolism. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-approach-to-slow-metabolism-middle-age
  27. Kalaichandran, A. (2023, March 21). A Step Towards Health: Unveiling the Link between Daily Steps, Sedentary Time, and Longevity. Rupa Health. https://www.rupahealth.com/post/a-step-towards-health-unveiling-the-link-between-daily-steps-sedentary-time-and-longevity
  28. Kaul K, Apostolopoulou M, Roden M. Insulin resistance in type 1 diabetes mellitus. Metabolism. 2015;64(12):1629-1639. https://pubmed.ncbi.nlm.nih.gov/26455399/
  29. Khakham, C. (2023, March 28). An Integrative Approach to Kidney Disease. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-kidney-disease
  30. Khakham, C. (2023, August 11). Top Labs to Run Bi-Annually on Your Type 2 Diabetes Patients. Rupa Health. https://www.rupahealth.com/post/top-labs-to-run-bi-annually-on-your-type-2-diabetes-patients
  31. Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther. 2022;7(1):216. https://pubmed.ncbi.nlm.nih.gov/35794109/
  32. Liguori I, Russo G, Curcio F, et al. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018;13:757-772. https://pubmed.ncbi.nlm.nih.gov/29731617/
  33. Long AE, George G, Williams CL. Persistence of islet autoantibodies after diagnosis in type 1 diabetes. Diabet Med. 2021;38(12):e14712. https://pubmed.ncbi.nlm.nih.gov/34614253/
  34. Maholy, N. (2023, May 17). A Functional Medicine Eye Health Protocol: Testing, Supplements, and Best Nutrition. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-eye-health-protocol
  35. Maholy, N. (2023, May 23). A Functional Medicine Treatment Protocol for Metabolic Syndrome: Testing, Nutrition, and Supplements. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-treatment-protocol-for-metabolic-syndrome-testing-nutrition-and-supplements
  36. Miller RG, McGurnaghan SJ, Onengut-Gumuscu S, et al. Insulin resistance-associated genetic variants in type 1 diabetes. J Diabetes Complications. 2021;35(4):107842. https://pubmed.ncbi.nlm.nih.gov/33468396/
  37. MΓΌller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. https://pubmed.ncbi.nlm.nih.gov/31767182/
  38. Perara, H. (2024, April 11.) The Ultimate High-Fiber Foods List: Boost Your Health with These High-Fiber Choices. Rupa Health. https://www.rupahealth.com/post/ultimate-fiber-foods-list
  39. Polsky S, Ellis SL. Obesity, insulin resistance, and type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2015;22(4):277-282. https://pubmed.ncbi.nlm.nih.gov/26087341/
  40. Preston, J. (2023, September 22). How Is Chronic Inflammation Linked to Metabolic Dysfunction? Rupa Health. https://www.rupahealth.com/post/how-is-chronic-inflammation-linked-to-weight-gain
  41. Rahman MS, Hossain KS, Das S, et al. Role of Insulin in Health and Disease: An Update. Int J Mol Sci. 2021;22(12):6403. https://pubmed.ncbi.nlm.nih.gov/34203830/
  42. Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127(1):1-4. https://pubmed.ncbi.nlm.nih.gov/28045402/
  43. Ε imonienΔ— D, PlatΕ«kiene A, PrakapienΔ— E, RadzevičienΔ— L, Veličkiene D. Insulin Resistance in Type 1 Diabetes Mellitus and Its Association with Patient's Micro- and Macrovascular Complications, Sex Hormones, and Other Clinical Data. Diabetes Ther. 2020;11(1):161-174. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965600/
  44. Stanford, J. (2024, March 19). Exploring the Link Between Insulin Resistance and Obesity. Rupa Health. https://www.rupahealth.com/post/insulin-resistance-obesity
  45. Stanford, J. (2024, January 19). Functional Medicine Interventions for Obesity in Diabetic Patients: A Comprehensive Approach. Rupa Health. https://www.rupahealth.com/post/functional-medicine-interventions-for-obesity-in-diabetic-patients-a-comprehensive-approach
  46. Stanford, J. (2024, March 21). Insulin Resistance and Inflammation: Understanding the Connection. Rupa Health. https://www.rupahealth.com/post/insulin-resistance-and-inflammation-understanding-the-connection
  47. Stanford, J. (2024, February 15). Proinflammatory Foods: What to Avoid and Why? Rupa Health. https://www.rupahealth.com/post/pro-inflammatory-foods-what-to-avoid-and-why
  48. Stanford, J. (2024, February 19). The Hidden Perils of Refined Carbohydrates: What Every Healthcare Professional Needs to Know. Rupa Health. https://www.rupahealth.com/post/the-hidden-perils-of-refined-carbohydrates-what-every-healthcare-professional-needs-to-know
  49. Stanford, J. (2024, May 23). The Role of GLP-1 Receptor Agonists in Weight Loss: Mechanisms, Benefits, and Clinical Applications. Rupa Health. https://www.rupahealth.com/post/glp-1-receptor-agonists-weight-loss
  50. Stanford, J. (2024, February 13). Top 10 Anti-Inflammatory Foods to Include in Your Diet. Rupa Health. https://www.rupahealth.com/post/top-10-anti-inflammatory-foods-to-include-in-your-diet
  51. Stanford, J. (2024, May 22.) What Is Insulin Resistance, and What Is the Effect On the Body? Rupa Health. https://www.rupahealth.com/post/what-is-insulin-resistance-effects
  52. Straub RH. Interaction of the endocrine system with inflammation: a function of energy and volume regulation. Arthritis Res Ther. 2014;16(1):203. https://pubmed.ncbi.nlm.nih.gov/24524669/
  53. Sweetnich, J. (2023, May 14). Overview of the Pancreas: Top Conditions, Specialty Testing, and Integrative Medicine Treatment Options. Rupa Health. https://www.rupahealth.com/post/pancrease-101-with-testing-top-conditions
  54. Teeter, L. (2023, April 24). Functional Nutrition Strategies for Weight Management and Metabolic Health. Rupa Health. https://www.rupahealth.com/post/functional-nutrition-strategies-for-weight-management-and-metabolic-health
  55. Tingle, R. (2022, June 6). 10 Type 2 Diabetes Risk Factors You May Not Know About. Rupa Health. https://www.rupahealth.com/post/what-causes-type-2-diabetes
  56. Weinberg, JL. (2023, June 1). A Functional Medicine Non-Alcoholic Fatty Liver Disease (NAFLD) Protocol: Testing, Nutrition, and Supplements. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-non-alcoholic-fatty-liver-disease-nafld-protocol-testing-nutrition-and-supplements
  57. Weinberg, JL. (2023, March 7). An Integrative Medicine Approach to Diabetic Neuropathy. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-diabetic-neuropathy
  58. Weinberg, JL. (2024, May 21). Stress and Insulin Sensitivity: All You Need to Know. Rupa Health. https://www.rupahealth.com/post/s-insulin-sensitivity
  59. Wolosowicz M, Lukaszuk B, Chabowski A. The Causes of Insulin Resistance in Type 1 Diabetes Mellitus: Is There a Place for Quaternary Prevention?. Int J Environ Res Public Health. 2020;17(22):8651. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700208/
  60. Yoshimura, H. (2023, November 13). Guarding Your Health: Proactive Steps to Ward Off Insulin Resistance. Rupa Health. https://www.rupahealth.com/post/guarding-your-health-proactive-steps-to-ward-off-insulin-resistance
  61. Yoshimura, H. (2023, November 22). Nature’s Sweet or Factory’s Treat: What’s the Difference between Natural Sugars and Added Sugars? Rupa Health. https://www.rupahealth.com/post/natures-sweet-vs-factorys-treat-whats-the-difference-between-natural-sugars-and-added-sugars
  62. Yoshimura, H. (2023, November 7). The Remarkable Power of Exercise on Our Health: A Comprehensive Overview. Rupa Health. https://www.rupahealth.com/post/the-remarkable-power-of-exercise-on-our-health-a-comprehensive-overview
Order from 30+ labs in 20 seconds (DUTCH, Mosaic, Genova & More!)
We make ordering quick and painless β€” and best of all, it's free for practitioners.

Latest Articles

View more on Metabolic Management
Subscribe to the magazine for expert-written articles straight to your inbox
Join the thousands of savvy readers who get root cause medicine articles written by doctors in their inbox every week!
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Trusted Source
Rupa Health
Medical Education Platform
Visit Source
Visit Source
American Cancer Society
Foundation for Cancer Research
Visit Source
Visit Source
National Library of Medicine
Government Authority
Visit Source
Visit Source
Journal of The American College of Radiology
Peer Reviewed Journal
Visit Source
Visit Source
National Cancer Institute
Government Authority
Visit Source
Visit Source
World Health Organization (WHO)
Government Authority
Visit Source
Visit Source
The Journal of Pediatrics
Peer Reviewed Journal
Visit Source
Visit Source
CDC
Government Authority
Visit Source
Visit Source
Office of Dietary Supplements
Government Authority
Visit Source
Visit Source
National Heart Lung and Blood Institute
Government Authority
Visit Source
Visit Source
National Institutes of Health
Government Authority
Visit Source
Visit Source
Clinical Infectious Diseases
Peer Reviewed Journal
Visit Source
Visit Source
Brain
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Rheumatology
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the National Cancer Institute (JNCI)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Cardiovascular Magnetic Resonance
Peer Reviewed Journal
Visit Source
Visit Source
Hepatology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Clinical Nutrition
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Bone and Joint Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Kidney International
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Allergy and Clinical Immunology
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Chest
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Neurology, Neurosurgery & Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Blood
Peer Reviewed Journal
Visit Source
Visit Source
Gastroenterology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Respiratory and Critical Care Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Diabetes Care
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of the American College of Cardiology (JACC)
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Clinical Oncology (JCO)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Clinical Investigation (JCI)
Peer Reviewed Journal
Visit Source
Visit Source
Circulation
Peer Reviewed Journal
Visit Source
Visit Source
JAMA Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
PLOS Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Nature Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The BMJ (British Medical Journal)
Peer Reviewed Journal
Visit Source
Visit Source
The Lancet
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the American Medical Association (JAMA)
Peer Reviewed Journal
Visit Source
Visit Source
Pubmed
Comprehensive biomedical database
Visit Source
Visit Source
Harvard
Educational/Medical Institution
Visit Source
Visit Source
Cleveland Clinic
Educational/Medical Institution
Visit Source
Visit Source
Mayo Clinic
Educational/Medical Institution
Visit Source
Visit Source
The New England Journal of Medicine (NEJM)
Peer Reviewed Journal
Visit Source
Visit Source
Johns Hopkins
Educational/Medical Institution
Visit Source
Visit Source

Hey practitioners! πŸ‘‹ Join Dr. Chris Magryta and Dr. Erik Lundquist for a comprehensive 6-week course on evaluating functional medicine labs from two perspectives: adult and pediatric. In this course, you’ll explore the convergence of lab results across different diseases and age groups, understanding how human lab values vary on a continuum influenced by age, genetics, and time. Register Here! Register Here.

Hey practitioners! πŸ‘‹ Join Dr. Terry Wahls for a 3-week bootcamp on integrating functional medicine into conventional practice, focusing on complex cases like Multiple Sclerosis. Learn to analyze labs through a functional lens, perform nutrition-focused physical exams, and develop personalized care strategies. Register Here.